DataMEDS AI Enters Amended and Restated LOI to License and Acquire IP Across Telehealth, Medical Drones and Healthcare Blockchain
DataMEDS AI, Inc. (NASDAQ:MEDS) announced on October 22, 2026 that it entered into an amended and restated non-binding letter of intent dated October 19, 2026 with Datavault AI Inc. (NASDAQ:DVLT), Data Health Partners, Inc. (including its REBOOT Health AI, Inc. subsidiary), EOS Technology Holdings, Inc., Scilex Holding Company (NASDAQ:SCLX) and HealthBridge Advisors, LLC to license and acquire intellectual property covering goal-driven prescription drug telehealth, medical drone delivery and healthcare blockchai...
Key takeaways
Non-binding amended and restated LOI dated October 19, 2026 supersedes the prior amended and restated LOI dated July 29, 2026, which expired September 30, 2026.
Transaction combines five separate IP/license/equity components: expanded exclusive Datavault AI healthcare license, QOLPOM IP from EOS, QOLPOM IP from Scilex, exclusive DHP/REBOOT IP license, and controlling interest in Tollo Health (d/b/a Health Lives Here) from HealthBridge Advisors.
Targeted proprietary IP position extends until at least 2042.
Related-party elements disclosed: Gerald Commissiong is CEO of Tollo Health and Interim Co-CEO of DataMEDS and sole owner of Fortitude Advisors; Nathaniel Bradley is CEO of both Datavault AI and EOS.
A majority of DataMEDS shareholders have approved the draft definitive agreements, subject to satisfactory completion of due diligence.
Industry context cited from Research and Markets: market projected to grow from $9.6 billion in 2025 to $93.4 billion by 2035.
Customer acquisition plan leverages existing relationship with NFL Alumni Health; distribution network cited at 6,500 independent pharmacies via subsidiary Corexa Health.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.